Estrogen-Receptor Antagonists for Treatment and Re-Sensitization of Anti-Estrogen Resistant Breast Cancers

Categories: “Cancer Therapeutics

Reference #: 2012-003

OTC Contact: Ruchika Nijhara, Ph.D., MBA, CLP (Directory Information | Send a Message)


Resistance to anti-estrogenic therapies remains as a very significant problem in the treatment of breast cancer. The present invention describes small molecules for the treatment or prevention of breast cancer. These compounds are effective against anti-estrogen resistant cells, and most remarkably, restore the sensitivity of Tamoxifen and Fulvestrant-resistant cells to Tamoxifen and Fulvestrant.


Potential treatment or prevention of breast cancers, endometrial cancers, and other cancers.


  • Potential therapeutic for anti-estrogen resistant cancers
  • Can restore sensitivity to Tamoxifen and Fulvestrant
  • Can be used alone or in conjunction with Tamoxifen

Stage of Development

Researchers have identified compounds that inhibit ER-α activity in multiple cell lines. Mechanism of action studies have been completed.

Relevant Publications

Manuscript is in preparation

Patent Status

Patent application filed.